Sun Pharma to unveil its version of Vortioxetine in India; inks pact with Lundbeck

30 Mar 2022 , 02:54 PM

Sun Pharmaceutical Industries Limited announced that one of its wholly-owned subsidiaries has inked an exclusive patent licensing agreement with H. Lundbeck A/S (“Lundbeck”) to market and distribute its own version of Vortioxetine in India under the brand name, VORTIDIF. This licensing agreement will only cover India.

Vortioxetine works as a novel antidepressant with multimodal activity, which can be used for the treatment of Major Depressive Disorder (MDD) in adults. The product is already approved in over 80 countries including the EU, Canada, the US, and Australia.

“Sun Pharma is the leader in neuro-psychiatry therapy in India and we always strive to bring innovative medicines that cater to the needs of patients. MDD is a serious and complicated disorder and VORTIDIFTM will prove to be an important novel treatment option for patients in India,” commented Kirti Ganorkar, CEO of India Business, Sun Pharma.

MDD, being one of the leading causes of disability, is impacting approximately 246 million people globally2 and 35 million people in India.

Sun Pharma is ranked No. 1 in terms of prescriptions and value amongst Neurologists & Psychiatrists in India (IMS MAT Jan 2022).

Sun Pharma is currently trading at Rs920.20 up by Rs0.7 or 0.08% from its previous closing of Rs919.50 on the BSE.